News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Significant Racial, Ethnic Related Socioeconomic Disparities Influence Survival in AML

Original Publication Date
Article Source
External Web Content
Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area. Significant disparities were found…

GTB-3550 TriKE Stimulates Natural Killer Cell Function in MDS and AML

Original Publication Date
Article Source
External Web Content
December 5, 2020 - GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia. GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk…

Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era

Original Publication Date
Article Source
External Web Content
Abstract Objective/Background Relapse is the most common cause of treatment failure after allogeneic hematopoietic cell transplantation (alloHCT). No standard of care exists, and a wide range of treatments are used for post-alloHCT relapse. In the recent era, several novel…

Targeted therapy venetoclax improving acute myeloid leukemia treatment options

Original Publication Date
Article Source
External Web Content
Targeted therapies are designed to work against specific vulnerabilities in a cancer cell. The targeted therapy drug venetoclax is designed to block the function of the B-cell lymphoma-2 (Bcl-2) protein, which normally works to prevent cell death. Venetoclax was first approved in…

NCCN Grants Category 2A Recommendation to Decitabine/Cedazuridine Combo for MDS

Original Publication Date
Article Source
External Web Content
The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS) to include the combination of decitabine and cedazuridine (Inqovi) as a category 2a recommendation for the treatment of adult patients with…

Benefits of Hematopoietic Stem Cell Transplantation in Advanced Myelodysplastic Syndromes

Original Publication Date
Article Source
External Web Content
Among fit older adults with advanced myelodysplastic syndromes (MDS) undergoing hematopoietic stem cell transplantation (HSCT), survival is significantly improved when transplantation is performed early or for adverse risk disease but not for patients with standard risk disease…

Seventh International Bone Marrow Failure Scientific Symposium - Summary for Patients

Original Publication Date
Article Source
AAMDSIF Web Content
We are pleased to present this Summary for Patients of the Seventh AAMDSIF International Bone Marrow Failure Scientific Symposium held virtually on July 15, 16 & 17, 2020. Our Symposium brought together many of the worldʼs leading experts on the biology and treatment of aplastic…

Human and artificial intelligence to illuminate MDS

Original Publication Date
Article Source
External Web Content
In this issue of Blood, Nagata et al show for the first time that machine learning (ML) algorithms can discern patterns and identify diagnostically and prognostically relevant associations between genetic variants and cytomorphological changes in myelodysplastic syndromes (MDS)…

New Strategies Improve Outcomes for Lower-Risk MDS

Original Publication Date
Article Source
External Web Content
Myelodysplastic syndrome (MDS) is a challenging and complicated disease with median outcomes ranging from 5.3 years in patients with lower-risk disease to just 8.4 months in the very high-risk population. 1,2 However, newly approved agents entering the armamentarium are providing…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families